Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway

Journal of Biological Chemistry

Volumn 288, Issue 25, 2013, Pages 17954-17967

  Balanis, Nikolas ^a   Wendt, Michael K ^b   Schiemann, Barbara J ^b   Wang, Zhenghe ^b   Schiemann, William P ^b   Carlin, Cathleen R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST CANCER CELLS; EPITHELIAL TO MESENCHYMAL TRANSITIONS; EXTRACELLULAR MATRICES; GROWTH FACTOR; MULTIPLE PATHWAYS; RECEPTOR SIGNALING; SIGNALING PATHWAYS;

SIGNALING;

DISEASES;

BETA1 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; JANUS KINASE 2; PROTEIN TYROSINE KINASE; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL ADHESION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BREAST CANCER; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); EPITHELIAL TO MESENCHYMAL TRANSITION; FIBRONECTIN; INTEGRIN; JAK2; STAT3;

ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBRONECTINS; FOCAL ADHESION KINASE 2; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; JANUS KINASE 2; MICE; MICE, NUDE; NIH 3T3 CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84880078474     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.475277     Document Type: Article

References (61)

1. Nelson, C. M., and Bissell, M. J. (2006) Of extracellular matrix, scaffolds, and signaling. Tissue architecture regulates development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 22, 287-309
2. Barkan, D., Green, J. E., and Chambers, A. F. (2010) Extracellular matrix.A gatekeeper in the transition from dormancy to metastatic growth. Eur. J. Cancer 46, 1181-1188
3. Cabodi, S., Moro, L., Bergatto, E., Boeri Erba, E., Di Stefano, P., Turco, E., Tarone, G., and Defilippi, P. (2004) Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem. Soc. Trans. 32, 438-442 (Pubitemid 38813532)
4. Streuli, C. H., and Akhtar, N. (2009) Signal co-operation between integrins and other receptor systems. Biochem. J. 418, 491-506
5. Balanis, N., Yoshigi, M., Wendt, M. K., Schiemann, W. P., and Carlin, C. R. (2011) β3 Integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Mol. Biol. Cell 22, 4288-4301
6. Galliher, A. J., Neil, J. R., and Schiemann, W. P. (2006) Role of transforming growth factor-β in cancer progression. Future Oncol. 2, 743-763 (Pubitemid 44941992)
7. Wendt, M. K., Smith, J. A., and Schiemann, W. P. (2010) Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29, 6485-6498
8. Quintela, I., Corte, M. D., Allende, M. T., Vazquez, J., Rodríguez, J. C., Bongera, M., Lamelas, M., Gonzalez, L. O., Vega, A., García-Muñiz, J. L., Astudillo, A., and Vizoso, F. (2005) Expression and prognostic value of EGFR in invasive breast cancer. Oncol. Rep. 14, 1655-1663
9. Ueno, N. T., and Zhang, D. (2011) Targeting EGFR in triple negative breast cancer. J. Cancer 2, 324-328
10. Wyckoff, J., Wang, W., Lin, E. Y., Wang, Y., Pixley, F., Stanley, E. R., Graf, T., Pollard, J. W., Segall, J., and Condeelis, J. (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 64, 7022-7029 (Pubitemid 39331012)
11. Flynn, J. F., Wong, C., and Wu, J. M. (2009) Anti-EGFR therapy. Mechanism and advances in clinical efficacy in breast cancer. J. Oncol. 2009, 526963
12. Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., Wolff, A. C., Hobday, T. J., Ivanova, A., Chiu, W. K., Ferraro, M., Burrows, E., Bernard, P. S., Hoadley, K. A., Perou, C. M., and Winer, E. P. (2012) TBCRC 001. Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J. Clin. Oncol. 30, 2615-2623
13. Wendt, M. K., Taylor, M. A., Schiemann, B. J., and Schiemann, W. P. (2011) Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol. Biol. Cell 22, 2423-2435
14. Ioachim, E., Charchanti, A., Briasoulis, E., Karavasilis, V., Tsanou, H., Ar-vanitis, D. L., Agnantis, N. J., and Pavlidis, N. (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer. Their prognostic value and role in tumour invasion and progression. Eur. J. Cancer 38, 2362-2370 (Pubitemid 35387487)
15. Ignotz, R. A., and Massagué, J. (1986) Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 261, 4337-4345 (Pubitemid 17198877)
16. Marotta, L. L., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., Wu, Z., Gönen, M., Mulvey, L. A., Bessarabova, M. O., Huh, S. J., Silver, S. J., Kim, S. Y., Park, S. Y., Lee, H. E., Anderson, K. S., Richardson, A. L., Nikolskaya, T., Nikolsky, Y., Liu, X. S., Root, D. E., Hahn, W. C., Frank, D. A., and Polyak, K. (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44CD24 stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121, 2723-2735
17. Idowu, M. O., Kmieciak, M., Dumur, C., Burton, R. S., Grimes, M. M., Powers, C. N., and Manjili, M. H. (2012) CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol. 43, 364-373
18. Kamimura, D., Ishihara, K., and Hirano, T. (2003) IL-6 signal transduction and its physiological roles. The signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149, 1-38
19. Fossey, S. L., Bear, M. D., Kisseberth, W. C., Pennell, M., and London, C. A. (2011) OncostatinMpromotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 11, 125
20. Ho, H. H., and Ivashkiv, L. B. (2006) Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 281, 14111-14118 (Pubitemid 43848338)
21. Guren, T. K., Abrahamsen, H., Thoresen, G. H., Babaie, E., Berg, T., and Christoffersen, T. (1999) EGF-induced activation of Stat1, Stat3, and Stat5b is unrelated to the stimulation of DNA synthesis in cultured hepatocytes. Biochem. Biophys. Res. Commun. 258, 565-571 (Pubitemid 29290308)
22. Wendt, M. K., Schiemann, B. J., Parvani, J. G., Lee, Y. H., Kang, Y., and Schiemann, W. P. (2013) TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene 32, 2005-2015
23. Liao, H. J., and Carpenter, G. (2009) Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res. 69, 6179-6183
24. Pruss, R. M., and Herschman, H. R. (1977) Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. Proc. Natl. Acad. Sci. U.S.A. 74, 3918-3921 (Pubitemid 8193535)
25. Kostenko, O., Tsacoumangos, A., Crooks, D., Kil, S. J., and Carlin, C. (2006) Gab1 signaling is regulated by EGF receptor sorting in early endosomes. Oncogene 25, 6604-6617 (Pubitemid 44646188)
26. Wendt, M. K., and Schiemann, W. P. (2009) Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis. Breast Cancer Res. 11, R68
27. Crooks, D., Kil, S. J., McCaffery, J. M., and Carlin, C. (2000) E3-13.7 integral membrane proteins encoded by human adenoviruses alter epidermal growth factor receptor trafficking by interacting directly with receptors in early endosomes. Mol. Biol. Cell 11, 3559-3572
28. Mendez, M. G., Kojima, S., and Goldman, R. D. (2010) Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 24, 1838-1851
29. Peris, L., Thery, M., Fauré, J., Saoudi, Y., Lafanechère, L., Chilton, J. K., Gordon-Weeks, P., Galjart, N., Bornens, M., Wordeman, L., Wehland, J., Andrieux, A., and Job, D. (2006) Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus ends. J. Cell Biol. 174, 839-849 (Pubitemid 44373733)
30. Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., and Pietenpol, J. A. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750-2767
31. Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J. P., Tong, F., Speed, T., Spellman, P. T., DeVries, S., Lapuk, A., Wang, N. J., Kuo, W. L., Stilwell, J. L., Pinkel, D., Albertson, D. G., Waldman, F. M., McCormick, F., Dickson, R. B., Johnson, M. D., Lippman, M., Ethier, S., Gazdar, A., and Gray, J. W. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (Pubitemid 44854747)
32. Irizarry, R. A., Hobbs, B., Collin, F., Beazer-Barclay, Y. D., Antonellis, K. J., Scherf, U., and Speed, T. P. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264
33. Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., and Szallasi, Z. (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725-731
34. Kil, S. J., Hobert, M., and Carlin, C. (1999) A leucine-based determinant in the epidermal growth factor receptor juxtamembrane domain is required for the efficient transport of ligand-receptor complexes to lysosomes. J. Biol. Chem. 274, 3141-3150 (Pubitemid 29075402)
35. Kil, S. J., and Carlin, C. (2000) EGF receptor residues Leu679, Leu680 mediate selective sorting of ligand-receptor complexes in early endocytic compartments. J. Cell Physiol. 185, 47-60
36. Coffer, P. J., and Kruijer, W. (1995) EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem. Biophys. Res. Commun. 210, 74-81
37. Ng, D. C., Lin, B. H., Lim, C. P., Huang, G., Zhang, T., Poli, V., and Cao, X. (2006) Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J. Cell Biol. 172, 245-257 (Pubitemid 43112971)
38. McMurray, J. S. (2006) A new small-molecule Stat3 inhibitor. Chem. Biol. 13, 1123-1124 (Pubitemid 44750737)
39. Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos-Hoff, M. H., Petersen, O. W., Gray, J. W., and Bissell, M. J. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 1, 84-96 (Pubitemid 46776616)
40. Dawson, P. J., Wolman, S. R., Tait, L., Heppner, G. H., and Miller, F. R. (1996) MCF10AT. A model for the evolution of cancer from proliferative breast disease. Am. J. Pathol. 148, 313-319
41. Cailleau, R., Olivé, M., and Cruciger, Q. (1978) Long-term human breast carcinoma cell lines of metastatic origin. Preliminary characterization. In Vitro 14, 911-915 (Pubitemid 9089089)
42. Lo, H. W., Hsu, S. C., Xia, W., Cao, X., Shih, J. Y., Wei, Y., Abbruzzese, J. L., Hortobagyi, G. N., and Hung, M. C. (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 67, 9066-9076 (Pubitemid 47535891)
43. Filmus, J., Trent, J. M., Pollak, M. N., and Buick, R. N. (1987) Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants. Mol. Cell Biol. 7, 251-257 (Pubitemid 17230407)
44. Padua, D., Zhang, X. H., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., and Massagué, J. (2008) TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77 (Pubitemid 351442989)
45. Hynes, R. O., Lively, J. C., McCarty, J. H., Taverna, D., Francis, S. E., Hodivala-Dilke, K., and Xiao, Q. (2002) The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb. Symp. Quant. Biol. 67, 143-153 (Pubitemid 36775506)
46. Barkan, D., Kleinman, H., Simmons, J. L., Asmussen, H., Kamaraju, A. K., Hoenorhoff, M. J., Liu, Z. Y., Costes, S. V., Cho, E. H., Lockett, S., Khanna, C., Chambers, A. F., and Green, J. E. (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68, 6241-6250
47. Shibue, T., and Weinberg, R. A. (2009) Integrin β1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl. Acad. Sci. U.S.A. 106, 10290-10295
48. Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., and Narod, S. A. (2007) Triplenegative breast cancer. Clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429-4434 (Pubitemid 47219710)
49. Tischkowitz, M., Brunet, J. S., Bégin, L. R., Huntsman, D. G., Cheang, M. C., Akslen, L. A., Nielsen, T. O., and Foulkes, W. D. (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7, 134
50. Dickler, M. N., Rugo, H. S., Eberle, C. A., Brogi, E., Caravelli, J. F., Panageas, K. S., Boyd, J., Yeh, B., Lake, D. E., Dang, C. T., Gilewski, T. A., Bromberg, J. F., Seidman, A. D., D'Andrea, G. M., Moasser, M. M., Melisko, M., Park, J. W., Dancey, J., Norton, L., and Hudis, C. A. (2008) A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin. Cancer Res. 14, 7878-7883
51. Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., Elvassore, N., and Piccolo, S. (2011) Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183
52. Tsonis, A. I., Afratis, N., Gialeli, C., Ellina, M. I., Piperigkou, Z., Skandalis, S. S., Theocharis, A. D., Tzanakakis, G. N., and Karamanos, N. K. (2013) Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells. FEBS J. 280, 2248-2259
53. Song, R. X., Chen, Y., Zhang, Z., Bao, Y., Yue, W., Wang, J. P., Fan, P., and Santen, R. J. (2010) Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J. Steroid Biochem. Mol. Biol. 118, 219-230
54. Ibrahim, S. A., Yip, G. W., Stock, C., Pan, J. W., Neubauer, C., Poeter, M., Pupjalis, D., Koo, C. Y., Kelsch, R., Schüle, R., Rescher, U., Kiesel, L., and Götte, M. (2012) Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase-and E-cadherin-dependent mechanism. Int. J. Cancer 131, E884-896
55. Rousseau, C., Ruellan, A. L., Bernardeau, K., Kraeber- Bodéré, F., Gouard, S., Loussouarn, D., Saï-Maurel, C., Faivre-Chauvet, A., Wijdenes, J., Barbet, J., Gaschet, J., Chérel, M., and Davodeau, F. (2011) Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. EJNMMI Res. 1, 20
56. Qian, X. L., Li, Y. Q., Yu, B., Gu, F., Liu, F. F., Li, W. D., Zhang, X. M., and Fu, L. (2013) Syndecan Binding Protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation. PLoS One 8, e60046
57. Zhu, T., Goh, E. L., and Lobie, P. E. (1998) Growth hormone stimulates the tyrosine phosphorylation and association of p125 focal adhesion kinase (FAK) with JAK2. Fak is not required for STAT-mediated transcription. J. Biol. Chem. 273, 10682-10689 (Pubitemid 28227682)
58. Takaoka, A., Tanaka, N., Mitani, Y., Miyazaki, T., Fujii, H., Sato, M., Kovarik, P., Decker, T., Schlessinger, J., and Taniguchi, T. (1999) Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-γ, but not IFN-α, signaling. EMBO J. 18, 2480-2488 (Pubitemid 29228484)
59. Singh, A., and Settleman, J. (2010) EMT, cancer stem cells and drug resistance. An emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751
60. Dana Farber Cancer Institute (March 28, 2012) Ruxolitinib in patients with breast cancer. National Library of Medicine (US), www.clinicaltrials. gov/show/NCT01562873, NLM identifier: NCT0004451
61. Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., and Lynch, M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129-3140